Latest filing published 06 Jun 2025 for NovoCure Ltd. Read the official filing
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Timothy J. Scannell (chief executive) discloses dealings in 5 companies, chiefly Stryker Corp, Insulet Corp and Novocure Ltd. The record holds 82 filings, for trades running from 29 January 2016 to 4 June 2025.
On the market, this insider has only sold: 20 sales, €17.1M in total. The rest of the record consists of 35 share grants and 27 option exercises. Since January 2025: no purchases and 1 sale on the market.
The latest filing, published on 6 June 2025, reports a share grant in Novocure Ltd. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. The legal deadline for a Form 4 is two business days after the transaction. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
17 of 17 declarations